Andes hantavirus - A primer - PubMed

3 hours ago

Andes hantavirus is the topic of a primer article, indicated by its mention in the title and DOI reference.
The article is published with a PMID of 42249060 and a DOI of 10.1038/s44298-026-00201-9, suggesting it is a scholarly publication.
There is a detailed conflict of interest statement disclosing financial interests and personal relationships of the authors, particularly FK.
FK is affiliated with the Icahn School of Medicine at Mount Sinai, which holds patents related to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics.
Mount Sinai has established a spin-out company named Castlevax for developing SARS-CoV-2 vaccines, with FK serving as co-founder and scientific advisory board member.
FK has consulting roles with multiple pharmaceutical and biotechnology companies including Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus, Pfizer, 3rd Rock Ventures, and Avimex.
The Krammer laboratory is engaged in collaborations with Dynavax on influenza vaccine development and with Sanofi on SARS-CoV-2 variant monitoring.
The text mentions 'LinkOut - more resources' and 'Full Text Sources', indicating additional materials or references are available for further reading.

Hasty Briefsbeta